South and Central America Non-Alcoholic Steatohepatitis Market

The South & Central America Non-Alcoholic Steatohepatitis market is expected to reach US$ 303.88 million by 2028 from US$ 44.76 million in 2021. The market is estimated to grow at a CAGR of 31.5% from 2021 to 2028.

There is a growing trend in collaborations among pharmaceutical companies to broaden combination therapies. Monotherapy is probable to put up modest or equivocal data and, therefore, will now no longer be a powerful therapy. This is because of NASH’s complex pathophysiology (oxidant stress, inflammation activation, fibrogenesis, microbiome, increased intestinal perSAMbility, and immune cell mechanisms) that affect the heterogeneity of phenotypes. Hence, the improvement of a single therapy for NASH appears complex and unlikely, regardless of the plethora of later-stage trials because of the report. Several drugs are presently being tested with Farnesoid X receptor (FXR) agonists. For instance, the combinations of Tropifexor/CVC (Allergan and Novartis), Semaglutide/Cilofexor/Firsocostat (Novo Nordisk and Gilead), and Selonsertib/Cilofexor/Firsocostat (Gilead, now discontinued). Novartis is recruiting 380 NASH patients with stage 2 or 3 Clinical Research Network (CRN) fibrosis in other drug combination trials to evaluate Licogliflozin, an SGLT1/2 inhibitor, and Tropifexor in combination or alone with a Phase 2 ELIVATE clinical trial, that is anticipated to finish by 2023. Metacrine Inc. compares other FXR agonists, MET409, in a Phase 2a combination trial (ClinicalTrials.gov NCT04702490) with an SGLT2 inhibitor-Empagliflozin (Jardiance) in patients with NASH and T2D. Pfizer Inc has taken into consideration combination therapies as properly and assessed the impact of PF-06865571 (a DGAT2 inhibitor) and PF-05221304 (an ACC inhibitor) on whole-liver fats in subjects with NAFLD in comparison to placebo in a short, 6-week Phase 2a clinical trial (ClinicalTrials.gov NCT03776175). Both drugs alone and in combination considerably decreased liver fats compared to placebo; however, there is no evidence of additivity (or synergy) with no huge differences among each monotherapy compared with the combination therapy. By the end of 2020, Pfizer conveyed that PF-05221304 was no longer in its pipeline and was discontinued as a monotherapy. Furthermore, Pfizer recently included a Phase 1 clinical trial of their pipeline to evaluate PF-06882961 (Danuglipron), a GLP-1R agonist in combination with PF-06865571, for the treatment of NASH. Thus, growing clinical trials involving combination studies of drugs are expected to emerge as a trend in the forecast period.The South & Central America non-alcoholic steatohepatitis market is expected to grow at a good CAGR during the forecast period.

South & Central America Non-Alcoholic Steatohepatitis Revenue and Forecast to 2028 (US$ Million)

  

South & Central America Non-Alcoholic Steatohepatitis Market Segmentation   

The South & Central America Non-Alcoholic Steatohepatitis market segmented into product, application, sales channel and country. Based on product type the South & Central America Non-Alcoholic Steatohepatitis market is segmented into vitamin e and pioglitazone, ocaliva, elafibranor, selonsertib,cenicriviroc and others. The selonsertib & cenicriviroc segment is expected to be the fastest growing segment over the forecaste period.Based on application the South & Central America Non-Alcoholic Steatohepatitis market segmented into treatment and diagnosis. The treatment segment is dominated South & Central America Non-Alcoholic Steatohepatitis market in 2020. Based on sales channel, the South & Central America Non-Alcoholic Steatohepatitis market segmented into hospital pharmacy, online provider, and retail pharmacy. The retail pharmacy segment is dominated South & Central America Non-Alcoholic Steatohepatitis market in 2020. Based on country, the South & Central America non-alcoholic steatohepatitis market is segmented into Brazil, Argentina, and the rest of South & Central America. The Brazil dominated the South & Central America non-alcoholic steatohepatitis market in 2020.

Cadila Pharmaceutical, Intercept Pharmaceutical, Novartis AG, Galmed Pharmaceutical, GENFIT, Siemens Healthineers AG, and Laboratory Corporation of America Holdings are among the leading companies in the South & Central America non-alcoholic steatohepatitis market.